PDF herunterladen
Semin Vasc Med 2004; 04(4): 347-356
DOI: 10.1055/s-2004-869591
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Statins Effect on Smooth Muscle Cell Proliferation

Stefano Bellosta1 , Lorenzo Arnaboldi1 , Lorenzo Gerosa1 , Monica Canavesi1 , Rachele Parente1 , Roberta Baetta1 , Rodolfo Paoletti1 , Alberto Corsini1
  • 1Department of Pharmacological Sciences, University of Milan, Milan, Italy
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
29. April 2005 (online)

    Lizenzen und Reprints

ABSTRACT

Clinical trials have firmly established that 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors (statins) can induce regression of vascular atherosclerosis as well as reduction of cardiovascular-related morbidity and death in patients with and without coronary artery disease. These beneficial effects of statins are usually assumed to result from their ability to reduce cholesterol synthesis. However, because mevalonic acid is the precursor not only of cholesterol but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase may result in pleiotropic effects. Indeed, statins can interfere with major events involved in the formation and the evolution of atherosclerotic lesions, such as arterial myocyte migration and proliferation and cholesterol accumulation, independent of their hypolipidemic properties. The aim of this article is to focus on clinical and experimental data that show that statins possess effects beyond cholesterol lowering, particularly on arterial smooth muscle cell proliferation. The contribution of these direct vascular effects to the reduction of cardiovascular events observed in clinical trials with statins represents one of the major challenges for future studies to understand the antiatherosclerotic benefits of these agents.

KEYWORDS

HMG-CoA reductase inhibitors - atherosclerosis - cell growth - statin - hypolipidemic drugs

REFERENCES

  • 1 Grundy S M, Cleeman J I, Merz C N et al.. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.  Circulation. 2004;  110 227-239
    CrossrefPubMedGoogle Scholar
  • 2 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).  JAMA. 2001;  285 2486-2497
    CrossrefPubMedGoogle Scholar
  • 3 Prevention of coronary heart disease in clinical practice . Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention.  Eur Heart J. 1998;  19 1434-1503
    CrossrefPubMedGoogle Scholar
  • 4 Scott L J, Curran M P, Figgitt D P. Rosuvastatin: a review of its use in the management of dyslipidemia.  Am J Cardiovasc Drugs. 2004;  4 117-138
    PubMedGoogle Scholar
  • 5 McTaggart F, Buckett L, Davidson R et al.. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.  Am J Cardiol. 2001;  87 28B-32B
    PubMedGoogle Scholar
  • 6 Corsini A, Bellosta S, Baetta R et al.. New insights into the pharmacodynamic and pharmacokinetic properties of statins.  Pharmacol Ther. 1999;  84 413-428
    CrossrefPubMedGoogle Scholar
  • 7 Bellosta S, Paoletti R, Corsini A. History and development of HMG-CoA reductase inhibitors. In: Schmitz G, Torzewski M HMG-CoA Reductase Inhibitors. Basel; Birkhauser 2002: 1-17
    Google Scholar
  • 8 Goldstein J L, Brown M S. Regulation of the mevalonate pathway.  Nature. 1990;  343 425-430
    CrossrefPubMedGoogle Scholar
  • 9 Maltese W A. Posttranslational modification of proteins by isoprenoids in mammalian cells.  FASEB J. 1990;  4 3319-3328
    PubMedGoogle Scholar
  • 10 Glomset J A, Gelb M H, Farnsworth C C. Prenyl proteins in eukaryotic cells: a new type of membrane anchor.  Trends Biochem Sci. 1990;  15 139-142
    CrossrefPubMedGoogle Scholar
  • 11 Laufs U, Liao J K. Isoprenoid metabolism and the pleiotropic effects of statins.  Curr Atheroscler Rep. 2003;  5 372-378
    PubMedGoogle Scholar
  • 12 Davignon J. Beneficial cardiovascular pleiotropic effects of statins.  Circulation. 2004;  109 III39-III43
    PubMedGoogle Scholar
  • 13 Nakai D, Nakagomi R, Furuta Y et al.. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes.  J Pharmacol Exp Ther. 2001;  297 861-867
    PubMedGoogle Scholar
  • 14 Komai T, Shigehara E, Tokui T et al.. Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture.  Biochem Pharmacol. 1992;  43 667-670
    CrossrefPubMedGoogle Scholar
  • 15 Shaw M K, Newton R S, Sliskovic D R et al.. Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.  Biochem Biophys Res Commun. 1990;  170 726-734
    CrossrefPubMedGoogle Scholar
  • 16 Ross R. Atherosclerosis-an inflammatory disease.  N Engl J Med. 1999;  340 115-126
    CrossrefPubMedGoogle Scholar
  • 17 Pickering J G, Weir L, Jekanowski J, Kearney M A, Isner J M. Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization.  J Clin Invest. 1993;  91 1469-1480
    PubMedGoogle Scholar
  • 18 Gordon D, Reidy M A, Benditt E P, Schwartz S M. Cell proliferation in human coronary arteries.  Proc Natl Acad Sci USA. 1990;  87 4600-4604
    PubMedGoogle Scholar
  • 19 Miller M J, Kuntz R E, Friedrich S P et al.. Frequency and consequences of intimal hyperplasia in specimens retrieved by directional atherectomy of native primary coronary artery stenoses and subsequent restenoses.  Am J Cardiol. 1993;  71 652-658
    CrossrefPubMedGoogle Scholar
  • 20 O'Brien E R, Alpers C E, Stewart D K et al.. Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy.  Circ Res. 1993;  73 223-231
    PubMedGoogle Scholar
  • 21 Jackson C L, Schwartz S M. Pharmacology of smooth muscle cell replication.  Hypertension. 1992;  20 713-736
    PubMedGoogle Scholar
  • 22 Ip J H, Fuster V, Badimon L et al.. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation.  J Am Coll Cardiol. 1990;  15 1667-1687
    PubMedGoogle Scholar
  • 23 Bellosta S, Bernini F, Ferri N et al.. Direct vascular effects of HMG-CoA reductase inhibitors.  Atherosclerosis. 1998;  137(Suppl) S101-S109
    CrossrefPubMedGoogle Scholar
  • 24 Glomset J A, Farnsworth C C. Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes.  Annu Rev Cell Biol. 1994;  10 181-205
    CrossrefPubMedGoogle Scholar
  • 25 Farnsworth C C, Wolda S L, Gelb M H, Glomset J A. Human lamin B contains a farnesylated cysteine residue.  J Biol Chem. 1989;  264 20422-20429
    PubMedGoogle Scholar
  • 26 Raiteri M, Arnaboldi L, McGeady P et al.. Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation.  J Pharmacol Exp Ther. 1997;  281 1144-1153
    PubMedGoogle Scholar
  • 27 Soma M R, Donetti E, Parolini C et al.. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits.  Arterioscler Thromb. 1993;  13 571-578
    PubMedGoogle Scholar
  • 28 Soma M R, Parolini C, Donetti E, Fumagalli R, Paoletti R. Inhibition of isoprenoid biosynthesis and arterial smooth-muscle cell proliferation.  J Cardiovasc Pharmacol. 1995;  25(Suppl 4) S20-S24
    PubMedGoogle Scholar
  • 29 Bocan T M, Mazur M J, Mueller S B et al.. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation.  Atherosclerosis. 1994;  111 127-142
    CrossrefPubMedGoogle Scholar
  • 30 Gellman J, Ezekowitz M D, Sarembock I J et al.. Effect of lovastatin on intimal hyperplasia after balloon angioplasty: a study in an atherosclerotic hypercholesterolemic rabbit.  J Am Coll Cardiol. 1991;  17 251-259
    PubMedGoogle Scholar
  • 31 Zhu B Q, Sievers R E, Sun Y P, Isenberg W M, Parmley W W. Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits.  J Cardiovasc Pharmacol. 1992;  19 246-255
    PubMedGoogle Scholar
  • 32 Bandoh T, Mitani H, Niihashi M et al.. Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery.  Eur J Pharmacol. 1996;  315 37-42
    CrossrefPubMedGoogle Scholar
  • 33 Igarashi M, Takeda Y, Mori S et al.. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth.  Br J Pharmacol. 1997;  120 1172-1178
    PubMedGoogle Scholar
  • 34 Veinot J P, Edwards W D, Camrud A R et al.. The effects of lovastatin on neointimal hyperplasia following injury in a porcine coronary artery model.  Can J Cardiol. 1996;  12 65-70
    PubMedGoogle Scholar
  • 35 Corsini A, Pazzucconi F, Arnaboldi L et al.. Direct effects of statins on the vascular wall.  J Cardiovasc Pharmacol. 1998;  31 773-778
    CrossrefPubMedGoogle Scholar
  • 36 Corsini A, Pazzucconi F, Pfister P, Paoletti R, Sirtori C R. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin.  Lancet. 1996;  348 1584
    PubMedGoogle Scholar
  • 37 Tse F L, Jaffe J M, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers.  J Clin Pharmacol. 1992;  32 630-638
    PubMedGoogle Scholar
  • 38 Maltese W A, Defendini R, Green R A, Sheridan K M, Donley D K. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.  J Clin Invest. 1985;  76 1748-1754
    PubMedGoogle Scholar
  • 39 Soma M R, Baetta R, De Renzis M R et al.. In vivo enhanced antitumor activity of carmustine [N,N′-bis(2-chloroethyl)-N-nitrosourea] by simvastatin.  Cancer Res. 1995;  55 597-602
    PubMedGoogle Scholar
  • 40 Bernini F, Didoni G, Bonfadini G, Bellosta S, Fumagalli R. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages.  Atherosclerosis. 1993;  104 19-26
    CrossrefPubMedGoogle Scholar
  • 41 Comparato C, Altana C, Bellosta S et al.. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?.  Nutr Metab Cardiovasc Dis. 2001;  11 328-343
    PubMedGoogle Scholar
  • 42 Mintz G S, Popma J J, Pichard A D et al.. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study.  Circulation. 1996;  94 35-43
    CrossrefPubMedGoogle Scholar
  • 43 Scheller B, Schmitt A, Bohm M, Nickenig G. Atorvastatin stent coating does not reduce neointimal proliferation after coronary stenting.  Z Kardiol. 2003;  92 1025-1028
    CrossrefPubMedGoogle Scholar
  • 44 Farb A, Sangiorgi G, Carter A J et al.. Pathology of acute and chronic coronary stenting in humans.  Circulation. 1999;  99 44-52
    PubMedGoogle Scholar
  • 45 Walter D H, Schachinger V, Elsner M et al.. Effect of statin therapy on restenosis after coronary stent implantation.  Am J Cardiol. 2000;  85 962-968
    CrossrefPubMedGoogle Scholar
  • 46 Serruys P W, Foley D P, Jackson G et al.. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.  Eur Heart J. 1999;  20 58-69
    CrossrefPubMedGoogle Scholar
  • 47 Bertrand M E, McFadden E P, Fruchart J C et al.. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.  J Am Coll Cardiol. 1997;  30 863-869
    CrossrefPubMedGoogle Scholar
  • 48 Weintraub W S, Boccuzzi S J, Klein J L et al.. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group.  N Engl J Med. 1994;  331 1331-1337
    CrossrefPubMedGoogle Scholar
  • 49 Serruys P W, de Feyter P, Macaya C et al.. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.  JAMA. 2002;  287 3215-3222
    CrossrefPubMedGoogle Scholar
  • 50 Cannon C P, Braunwald E, McCabe C H et al.. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.  N Engl J Med. 2004;  350 1495-1504
    CrossrefPubMedGoogle Scholar
  • 51 Sata M, Nishimatsu H, Osuga J et al.. Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis.  Hypertension. 2004;  43 1214-1220
    CrossrefPubMedGoogle Scholar
  • 52 Ridker P M, Rifai N, Pfeffer M A, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.  Circulation. 1999;  100 230-235
    PubMedGoogle Scholar
  • 53 Sparrow C P, Burton C A, Hernandez M et al.. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering.  Arterioscler Thromb Vasc Biol. 2001;  21 115-121
    PubMedGoogle Scholar
  • 54 Romano M, Diomede L, Sironi M et al.. Inhibition of monocyte chemotactic protein-1 synthesis by statins.  Lab Invest. 2000;  80 1095-1100
    PubMedGoogle Scholar
  • 55 Kimura M, Kurose I, Russell J, Granger D N. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats.  Arterioscler Thromb Vasc Biol. 1997;  17 1521-1526
    PubMedGoogle Scholar
  • 56 O'Driscoll G, Green D, Taylor R R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.  Circulation. 1997;  95 1126-1131
    PubMedGoogle Scholar

Alberto CorsiniPh.D. 

Department of Pharmacological Sciences

University of Milan, Via Balzaretti 9

20133 Milan, Italy

eMail: alberto.corsini@unimi.it